// App-Quantinova.ai

DMT39 : Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial

Researchers

Presenter

  • Mali Coray

Principal Investigators

  • Andrea Seitzinger

  • Sanjeev Roy

  • Mark S Freedman

  • Frederik Barkhof

  • Giancarlo Comi

  • Nicola De Stefano

  • Ludwig Kappos

  • Jens Kuhle

  • Matthias Mehling

Medical Centers

  • Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada

  • Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland

  • Neurology Departments of Head, Spine and Neuromedicine, Biomedical Engineering and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland

  • Department of Radiology and Nuclear Medicine, MS Center Amsterdam, Amsterdam, Netherlands, UCL Institute of Neurology, London, United Kingdom

  • Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

  • Casa di Cura Privata del Policlinico, Università Vita-Salute San Raffaele, Milan, Italy

  • Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

  • Research Center for Clinical Neuroimmunology and Neuroscience, Basel, Switzerland

  • Ares Trading S.A, Eysins, Switzerland

  • The healthcare business of Merck KGaA, Darmstadt, Germany

Locations

  • Switzerland

  • Italy

  • United Kingdom

  • Germany

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Dermatology

Disease

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • Growth differentiation factor 15

  • Interferon

Drug/Treatment

  • Interferon

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved